Anti-rabies monoclonal antibody - Serum Institute of India/MassBiologics

Drug Profile

Anti-rabies monoclonal antibody - Serum Institute of India/MassBiologics

Alternative Names: RAB-1; Rabies human monoclonal antibody - Serum Institute of India; Rabishield; RMab; SII RMab

Latest Information Update: 04 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centers for Disease Control and Prevention; MassBiologics; University of Massachusetts Medical School
  • Developer Serum Institute of India
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 04 Oct 2016 Launched for Rabies in India (IM) before October 2016(Serum Institute of India, October 2016)
  • 06 Sep 2013 Isconova is now called Novavax AB
  • 22 Aug 2013 Isconova has been acquired by Novavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top